Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis
Seiichi Mawatari, Shiroh Tanoue, Kotaro Kumagai, Kohei Oda, Ai Toyodome, Haruka Sakae, Kunio Fujisaki, Yukiko Inada, Hirofumi Uto, Akiko Saisyoji, Yasunari Hiramine, Kazuaki Tabu, Sho Ijuin, Takeshi Hori, Tsutomu Tamai, Akihiro Moriuchi, Shuji Kanmura, Akio Ido · 2025
Read Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis by Seiichi Mawatari, Shiroh Tanoue, Kotaro Kumagai, Kohei Oda, Ai Toyodome, Haruka Sakae, Kunio Fujisaki, Yukiko Inada, Hirofumi Uto, Akiko Saisyoji, Yasunari Hiramine, Kazuaki Tabu, Sho Ijuin, Takeshi Hori, Tsutomu Tamai, Akihiro Moriuchi, Shuji Kanmura, Akio Ido (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12749750.txt.
Description
Direct-acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates in patients with hepatitis C virus (HCV) infection. However, the long-term prognosis and cause-specific mortality post-SVR remain unclear. This study analyzed 1753 HCV-infected patients without a history of hepatocellular carcinoma treatment who achieved SVR with DAAs and did not develop cancer.
Catalog record
| CREATOR | Seiichi Mawatari, Shiroh Tanoue, Kotaro Kumagai, Kohei Oda, Ai Toyodome, Haruka Sakae, Kunio Fujisaki, Yukiko Inada, Hirofumi Uto, Akiko Saisyoji, Yasunari Hiramine, Kazuaki Tabu, Sho Ijuin, Takeshi Hori, Tsutomu Tamai, Akihiro Moriuchi, Shuji Kanmura, Akio Ido |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |